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Objectives: To evaluate local joint variables after intra-articular injection with triamcinolone
hexacetonide in rheumatoid arthritis patients.
Methods: We  blindly and prospectively (baseline, 1, 4, 12 and 24 weeks) evaluated
metacarpophalangeal, wrist, elbow, shoulder, knee and ankle joints after triamcinolone hex-
acetonide intra-articular injection by the following outcome measures: visual analogue scale
0–10 cm (VAS) for rest pain (VASR); VAS for movement pain (VASM); VAS for joint swelling
(VASSw); ﬂexion (FlexG) and extension (ExtG).
Results: 289 patients (635 joints) were studied. VASSw (p < 0.001) and VASR (0.001 < p < 0.016)
improved from T0 to T4, T12 and T24 for all joints. VASM improved from T0 to T4 (p < 0.021)
for  all joints; T0 to T12 (p < 0.023) for MCF and knee; T0 to T24 (p < 0.019) only for MCF and
knee. FlexG improved from T0 to T4 (p < 0.001) for all joints; T0 to T12 (p < 0.001) and T0 to
T24 (p < 0.02) only for MCF and knee. ExtG improved from T0 to T4 (p < 0.001) for all joints
except for elbow; T0 to T12 (p = 0.003) for wrist, metacarpophalangeal and knee; and T0 to
T24  (p = 0.014) for MCF and knee.
Conclusion: VASSw responded better at short and medium term after IAI with triamcinolonehexacetonide in our sample of RA patients.
©  2016 Published by Elsevier Editora Ltda. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).BPlease cite this article in press as: Furtado RN, et al. Intra-articular injection with triamcinolone hexacetonide in patients
with rheumatoid arthritis: prospective assessment of goniometry and joint inﬂammation parameters. Rev Bras Reumatol. 2016.
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Injec¸ão intra-articular  de  hexacetonido  de  triancinolona  em  pacientes
com  artrite  reumatoide:  avaliac¸ão  prospectiva  da  goniometria  e
parâmetros  de  inﬂamac¸ão  articular
Palavras-chave:
Artrite reumatoide
Injec¸ões intra-articulares
Triamcinolona
Melhoria
r  e  s  u  m  o
Objetivos: Avaliar variáveis articulares locais após a inﬁltrac¸ão intra-articular (IIA) de hex-
acetonido de triancinolona (HT) em pacientes com artrite reumatoide (AR).
Métodos: Foram avaliadas, de modo cego e prospectivo (nos tempos inicial, 1, 4, 12 e 24 sem-
anas), as articulac¸ões metacarpofalângica (MCF), punho, cotovelo, ombro, joelho e tornozelo
após  a IIA de HT utilizando-se das seguintes medidas de desfecho: escala visual analógica
(EVA) de 0 a 10 cm para dor em repouso (EVAr); EVA para dor ao movimento (EVAm); EVA
para edema articular (EVAe); ﬂexão (FlexG) e extensão (ExtG).
Resultados: Estudaram-se 289 pacientes (635 articulac¸ões). A EVAe (p < 0,001) e a EVAr
(0,001 < p < 0,016) melhoraram de T0 a T4, T12 e T24 em todas as articulac¸ões. A EVAm mel-
horou de T0-T4 (p < 0,021) em todas as articulac¸ões; T0-T12 (p < 0,023) na MCF  e no joelho;
T0-T24 (p < 0,019) apenas na MCF e no joelho. A FlexG melhorou de T0-T4 (p < 0,001) em todas
as  articulac¸ões; T0-T12 (p < 0,001) e T0-T24 (p < 0,02) apenas na MCF e no joelho. A ExtG mel-
horou de T0-T4 (p < 0,001) em todas as articulac¸ões, exceto no cotovelo; T0-T12 (p = 0,003)
no  punho, na MCF e no joelho; e T0-T24 (p = 0,014) na MCF e no joelho.
Conclusão: A EVAe respondeu melhor em curto e médio prazos após a IIA de HT nessa
amostra de pacientes com AR.
© 2016 Publicado por Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma
c¸a  Clicen
Introduction
Intra-articular injection (IAI) with corticosteroids (CEs) has
been a very common practice among rheumatologists since
1951.1 It is usually used when mono or pauci-articular synovi-
tis persists.2
There are several CEs used in clinical practice. However,
over the decades, it has been observed in pharmacokinetic
studies that the CE with more  microcrystalline properties
remains longer in the joint.3
Thus, since 1961 triamcinolone esters have been used in IAI
for the treatment of refractory synovitis.2 Triamcinolone hex-
acetonide (TH) is the ﬂuorinated CE with the lowest solubility
and most atrophying properties among the CEs.3 However,
it is less utilized in comparison with other less atrophying
CEs.4–6Although IAI is widely used in clinical practice among
rheumatologists, little is known about predictors and local
variables (pain, swelling and goniometry) of best response to
IAI.
The aim of this study was to assess the response of vari-
ables such as joint pain, swelling and goniometry after IAI with
TH in short and medium terms in rheumatoid arthritis (RA)
patients.
Materials  and  methods
A prospective study was conducted in a cohort of 289 adult RA
patients7 with refractory synovitis who received TH IAI.
Patients were recruited from outpatient RA clinic from thePlease cite this article in press as: Furtado RN, et al. Intra-ar
with rheumatoid arthritis: prospective assessment of goniometry a
http://dx.doi.org/10.1016/j.rbre.2016.08.001
Rheumatology Division of the Universidade Federal de Sao
Paulo, Sao Paulo, Brazil. The Ethics Committee of this insti-
tution approved this study.C BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Inclusion criteria were: RA diagnosis according to the
American College of Rheumatology (ACR)7; age between
18 and 65 years; refractory synovitis (persistent pain and
swelling) in at least one of the following joints: metacar-
pophalangeal (MCP), wrist, elbow, shoulder, knee or ankle;
functional class II or III8; stable dose of DMARD for the
past three months; and stable dose of CE in the last month.
Patients were excluded if there was any suspicion of local
or systemic infection; severe clotting disorder; received any
IAI in the past 3 months before the study, or were clinically
decompensated from diseases such as diabetes mellitus or
hypertension. All patients have read, understood and agreed
to sign the informed consent form.
Intervention
IAI with TH was blindly performed after rigorous antisepsis
with topical povidone-iodine. We  used sterile and disposable
materials in all IAIs. The procedure was performed on a single
occasion (T0–baseline) by the same rheumatologist with 20
years of experience in interventional rheumatology.
The doses of TH used varied according to each joint:
shoulder, 80 mg  (4 mL); elbow 40 mg  to 60 mg  (2–3 mL); wrist,
30–40 mg  (1.5–2 mL); MCP joint, 10–20 mg  (0.5–1 mL); knee,
40–80 mg  (2–4 mL), ankle, 40–60 mg  (2–3 mL).9 The patients
underwent mono, pauci (up to 3 joints) or poly (4–8 joints) IAI
according to the number of joints with refractory synovitis at
the time of enrollment.
Assessmentticular injection with triamcinolone hexacetonide in patients
nd joint inﬂammation parameters. Rev Bras Reumatol. 2016.
Patient assessment was performed by a blinded observer,
unaware of the demographic characteristics of the joint dis-
ease and baseline variables of patients.
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Table 1 – Demographic, related to disease and related to
injection data of the baseline sample.
Variables
Age in years, mean (±SD) 47.64 (±10.8)
Disease duration in years, mean (±SD) 10.98 (±8.4)
Women: Men ratio 12:1
Global pain, VAS mean (±SD) 6.52 (±1.7)
HAQ, mean (±SD) 1.36 (0.6)
White skin color N (%) 308 (48.5)
Functional Class II N (%)/III N (%) 360 (56.7)/275 (43.3)
Monoarticular injetion N (%) 300 (47.2)
Pauciarticular injection N (%) 68 (23.5)
Poly-articular injection N (%) 312 (49.1)
Rheumatoid Factor positivity N (%) 416 (65.6)
Extra-articular disease N (%) 71 (11.2)
Previous IAIC N (%) 300 (47.2)
Number of joints through T4/T24:
Shoulder N 35/0
Elbow N 48/17
Wrist N 160/63
MCP N 142/103
Knee N 152/85
Ankle N 98/45
Patients/Joints evaluated from T0 to:
T4 289/635 joints
T12 185/403 joints
T24 35/313 joints
HAQ, Health Assessment Questionnaire; N (%), frequency (percent-r  e v b r a s r e u m a t o l
The assessment times were: T0 (baseline), T1 (1 week), T4
4 weeks), T12 (12 weeks) and T24 (24 weeks) after the IAI.
The following assessment instruments were used at each
ime of assessment: VAS (visual analogue scale, 0–10 cm)  for
oint pain at rest (VASR), VAS for joint pain during motion
VASM), VAS for joint swelling (VASSw); goniometry for ﬂex-
on (FlexG) and extension (ExtG) for all joints studied. The
houlder was not assessed for extension.
tatistical  analysis
he continuous variables were described in mean and
tandard deviation (SD) and the categorical variables in fre-
uencies and percentages.
Comparison of these percentages with continuous baseline
ariables was made using Kruskal–Wallis test, while com-
arison with baseline categorical variables was done using
hi-square or Fisher’s Exact test. These tests were used only
or same baseline demographic variables and not used in
he comparison of the repeated variables. For the assessment
f times of the most important continuous variables of the
resent study, e.g. VASR, VASM, VASSw, FlexG and ExtG, we
sed ANOVA with repeated measures. All statistical analyses
or these variables assessed at time points were carried out
sing ANOVA test with repeated measures.
p values were considered statistically signiﬁcant under
.05.
esults
wo hundred and eighty-nine RA patients were studied
rospectively, with a mean age of 47.6 years (±10.8); mean dis-
ase duration of 10.98 years (±8.4); 48.5% of the sample was
aucasian and the women to men  ratio was 12:1. Six hundred
nd thirty-ﬁve joints were included and studied between T0
nd T4, and 313 joints until T24. All joints assessed until T4,
ere also evaluated at T1, and all those assessed at T24 were
lso evaluated at T12.
We found no signiﬁcant differences in the proportion of left
nd right sides in the joints studied (p = 0.302, Chi-square test).
lso, we  found no signiﬁcant differences in age distribution
mong the different joints (p = 0.064, Kruskal–Wallis test).
The most studied joints at inclusion were wrists (160) and
he least studied were shoulders (35). On the other hand, the
oints most assessed at T24 were MCP  joints (103). The vari-
bles studied at T0; the distribution of mono and pauci or
oly-IAI and the number of assessed joints until T4 and T24
re shown in Table 1.
Tables 2–6 show the results of statistical analysis for
esponse to IAI with TH for each variable, VASR, VASM, VASSw,
lexG and ExtG. Statistical analysis was performed comparing
he time of assessment with T0 (baseline) for each variable.
VASR showed a very good response to IAI with TH and a
tatistically signiﬁcant improvement from T0 to T4 (p < 0.001);Please cite this article in press as: Furtado RN, et al. Intra-art
with rheumatoid arthritis: prospective assessment of goniometry a
http://dx.doi.org/10.1016/j.rbre.2016.08.001
0 to T12 (p < 0.012); and T0 to T24 (p < 0.016) for all joints stud-
ed. The improvement of the elbow from T0 to T12, and elbow
nd ankle from T0 to T24 were those rates with the lowest
tatistical signiﬁcance. This analysis is shown in Table 2.age); SD, standard deviation; IAIC, intra-articular injection with
corticosteroid; MCP, metacarpophalangeal; VAS, visual analogue
scale.
VASM presented the worst evolution compared to VASR in
the same joints. VASM showed improvement from T0 to T4
(p < 0.001) for all joints studied; from T0 to T12 (p < 0.023) for
the wrist, MCP  and knee; and from T0 to T24 (p < 0.019) only
for MCP and knee. The elbow was the only joint which VASM
did not improve after the IAI with TH from T0 to T24. The ankle
did not improve from T0 to T12, and the ankle and the wrist
showed no improvement from T0 to T24 (Table 3).
VASSw showed the best performance for all joints, at all
assessment times, as seen in Table 4. This variable improved
statistically from T0 to T4 (p < 0.001); T0 to T12 (p < 0.001); and
T0 to T24 (p < 0.001) for all joints, with the highest statistical
signiﬁcance (p < 0.001) (Table 4).
Joint goniometry responded worst to IAI with TH compared
to the other variables. FlexG improved from T0 to T4 (p < 0.001)
for all the joints. However, this improvement occurred only
for MCF and knee from T0 to T12 (p < 0.001) and from T0 to T24
(p < 0.011). In other words, in the medium term, this improve-
ment was not sustained. These data are seen in Table 5.
ExtG also responded worst to the IAI with TH compared to
pain and joint swelling. ExtG improved from T0 to T4 (p < 0.001)
for all joints except for the elbow; from T0 to T12 (p < 0.003) for
the wrist, MCP and knee; and from T0 to T24 (p < 0.014) for MCP
and knee (Table 6).icular injection with triamcinolone hexacetonide in patients
nd joint inﬂammation parameters. Rev Bras Reumatol. 2016.
Discussion
IAI is used for short-term treatment of refractory synovi-
tis, mainly mono and pauci-articular. TH is the CE with the
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Table 2 – Assessment of improvement in joint pain at rest (VASR) over time for each joint studied.
Joint VASR – Mean (±SD)
T0 T1 p T4 p T12 p T24 p
Shoulder
T0–T4 (n = 35) 5.42 (1.75) 1.68 (2.63) <0.001 0.80 (1.93) <0.001 – – – –
Elbow
T0–T4 (n = 48) 4.97 (2.50) 1.08 (1.85) <0.001 0.77 (1.65) <0.001 – – – –
T0–T24 (n = 17) 4.11 (3.47) 1.35 (2.14) 0.011 1.00 (1.83) 0.001 1.82 (2.74) 0.012 1.58 (2.39) 0.016
Wrist
T0–T4 (n = 160) 4.69 (2.54) 2.06 (2.36) <0.001 1.52 (2.17) <0.001 – – – –
T0–T24 (n = 63) 3.34 (3.15) 0.88 (1.85) <0.001 0.74 (1.66) <0.001 1.98 (2.73) 0.004 1.82 (2.39) <0.001
MCP
T0–T4 (n = 142) 2.98 (2.72) 0.98 (1.91) <0.001 0.54 (1.50) <0.001 – – – –
T0–T24 (n = 103) 2.24 (2.76) 0.94 (2.01) <0.001 0.48 (1.60) <0.001 0.76 (2.07) <0.001 0.79 (1.94) <0.001
Knee
T0–T4 (n = 152) 5.98 (2.29) 1.98 (2.22) <0.001 2.23 (3.30) <0.001 – – – –
T0–T24 (n = 85) 5.83 (2.62) 1.94 (2.20) <0.001 2.40 (2.61) <0.001 2.77 (2.79) <0.001 3.92 (3.06) <0.001
Ankle
T0–T4 (n = 98) 4.59 (2.65) 1.33 (2.16) <0.001 1.42 (2.43) <0.001 – – – –
T0–T24 (n = 45) 3.56 (3.15) 1.36 (2.21) <0.001 1.56 (2.63) 0.001 1.72 (2.38) 0.001 2.38 (2.80) 0.014
tion; VASR, visual analogue scale 0–10 cm for rest pain; SD, standard devia
Statistical test: ANOVA for repeated measures.
slowest joint clearance and the most potent in producing
synovial atrophy. However, it is also the most potential to
cause damage if injected into extra-articular tissue.3 It has
been proven its superiority over other intraarticular CE used
in RA and in osteoarthritis (OA) patients. Its use has been con-
sidered superior to the use of systemic CE when used in mono
or poly IAI in RA patients.10,11
Although it is a procedure widely used by rheumatologists,
there are few prospective studies comparing the effectivenessPlease cite this article in press as: Furtado RN, et al. Intra-ar
with rheumatoid arthritis: prospective assessment of goniometry a
http://dx.doi.org/10.1016/j.rbre.2016.08.001
of IAI with other interventions, or even with the systemic use
of other CE.10,11
By conducting this study, we  intended to identify the joint
variables which best responded to IAI with TH in the joints
Table 3 – Assessment of improvement in joint pain in motion (
Joint 
T0 T1 p T4 
Shoulder
T0–T4 (n = 35) 7.11 (1.62) 4.74 (2.47) <0.001 3.31 (2.7
Elbow
T0–T4 (n = 48) 5.70 (3.29) 2.66 (2.83) <0.001 1.93 (2.6
T0–T24 (n = 17) 2.05 (2.53) 0.88 (1.96) NS 0.58 (1.6
Wrist
T0–T4 (n = 160) 4.76 (3.11) 2.69 (2.67) <0.001 2.28 (2.5
T0–T24 (n = 63) 1.74 (2.40) 0.55 (1.58) <0.001 0.79 (1.8
MCP
T0–T4 (n = 142) 2.93 (3.18) 1.38 (2.19) <0.001 1.02 (2.0
T0–T24 (n = 103) 1.50 (2.30) 0.63 (1.66) 0.012 0.33 (1.2
Knee
T0–T4 (n = 152) 6.16 (2.37) 2.40 (2.37) <0.001 2.11 (2.3
T0–T24 (n = 85) 5.52 (2.69) 1.81 (2.22) <0.001 1.91 (2.4
Ankle
T0–T4 (n = 98) 5.30 (3.28) 2.85 (2.91) <0.001 2.80 (3.0
T0–T24 (n = 45) 2.44 (2.52) 0.77 (1.83) 0.003 0.88 (1.9
VASM, visual analogue scale 0–10 cm for pain in motion; SD, standard devi
Statistical test: ANOVA for repeated measures.MCP, metacarpophalangeal joint.
we considered relevant in RA patients, using “blinded” and
prospective assessments at short and mid-term.
It was observed that VASR improved from T0 to T4, T0 to
T12 and T0 to T24 for all injected joints. We  expected the rest
pain to be a variable well responsive to the IAI. Surprisingly,
VASM improved statistically for all joints only in the short
term (T0–T4). In the long term, this variable improved statisti-
cally, for only MCPs and knees. The difference in pain response
between VASR and VASM may be due to several factors. Pain onticular injection with triamcinolone hexacetonide in patients
nd joint inﬂammation parameters. Rev Bras Reumatol. 2016.
movement  may be a more  difﬁcult variable to treat because of
the stress resulting from the movement  of the inﬂamed joint.
Joint goniometry variables (FlexG and ExtG) responded
well to IAI with TH only in the short term, where statistical
VASM) over time for each joint studied.
VASM – Mean (±SD)
p T12 p T24 p
1) <0.001 – – – –
0) <0.001 – – – –
6) NS 0.29 (1.21) NS 0.58 (1.66) NS
7) <0.001 – – – –
4) 0.021 0.82 (1.83) 0.023 1.66 (2.37) NS
1) <0.001 – – – –
6) <0.001 0.38 (1.34) <0.001 0.67 (1.72) 0.019
9) <0.001 – – – –
9) <0.001 2.56 (2.66) <0.001 3.51 (3.18) <0.001
5) <0.001 – – – –
3) 0.002 1.66 (2.38) NS 2.22 (2.51) NS
ation; NS, no statistical difference; MCP, metacarpophalangeal joint.
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Table 4 – Assessment of improvement in joint swelling (VASSw) over time for each joint studied.
Joint VASSw – Mean (±SD)
T0 T1 p T4 p T12 p T24 p
Shoulder
T0–T4 (n = 35) 3.37 (1.64) 1.31 (0.99) <0.001 0.62 (0.77) <0.001 – – – –
Elbow
T0–T4 (n = 48) 5.47 (1.32) 2.04 (1.85) <0.001 1.43 (1.72) <0.001 – – – –
T0–T24 (n = 17) 5.47 (2.18) 1.17 (2.18) <0.001 1.47 (2.34) <0.001 1.47 (2.33) <0.001 0.88 (1.96) <0.001
Wrist
T0–T4 (n = 160) 5.27 (1.32) 2.83 (2.08) <0.001 2.23 (2.09) <0.001 – – – –
T0–T24 (n = 63) 5.27 (1.32) 2.46 (2.51) <0.001 1.98 (2.46) <0.001 3.33 (2.37) <0.001 3.57 (2.27) <0.001
MCP
T0–T4 (n = 142) 5.07 (0.84) 2.05 (2.23) <0.001 1.25 (1.92) <0.001 – – – –
T0–T24 (n = 103) 5.07 (0.84) 1.99 (2.45) <0.001 1.21 (2.15) <0.001 1.85 (2.41) <0.001 1.99 (2.45) <0.001
Knee
T0–T4 (n = 152) 4.58 (1.68) 1.93 (1.81) <0.001 1.30 (1.54) <0.001 – – – –
T0–T24 (n = 85) 4.17 (1.66) 1.48 (1.91) <0.001 1.05 (1.57) <0.001 1.17 (1.64) <0.001 1.50 (1.78) <0.001
Ankle
T0–T4 (n = 98) 5.56 (1.45) 2.71 (2.12) <0.001 2.31 (2.09) <0.001 – – – –
T0–T24 (n = 45) 5.47 (1.32) 2.11 (2.49) <0.001 1.88 (2.45) <0.001 2.66 (2.52) <0.001 2.77 (2.51) <0.001
 devi
r
m
a
t
w
h
c
p
s
r
VVASSw, visual analogue scale 0–10 cm for joint swelling; SD, standard
Statistical test: ANOVA for repeated measures.
esponses to all joints studied were observed. However, in the
edium term, the responses were statistically more  fragile
nd in a fewer number of joints. This ﬁnding may be due
o the fact that our sample was composed by RA patients
ith a mean length time of disease of almost 11 years. The
igh prevalence of long standing RA probably represented a
rucial factor for the goniometry outcomes. Long standing
atients like these may present severe structural damage andPlease cite this article in press as: Furtado RN, et al. Intra-art
with rheumatoid arthritis: prospective assessment of goniometry a
http://dx.doi.org/10.1016/j.rbre.2016.08.001
econdary osteoarthritis and this may have inﬂuenced the
esponse of goniometry variables FlexG and ExtG as well as
ASM.
Table 5 – Assessment of improvement in joint ﬂexion over time
Joint Joint ﬂexi
T0 T1 p T4
Shoulder
T0–T4 (n = 35) 137.42 (32.50) 148.25 (31.85) <0.001 156.14 (3
Elbow
T0–T4 (n = 48) 124.72 (12.20) 132.08 (10.14) <0.001 133.16 (8
T0–T24 (n = 17) 126.17 (10.82) 130.58 (11.97) NS 127.35 (6
Wrist
T0–T4 (n = 160) 42.46 (18.70) 45.57 (21.10) 0.005 47.73 (1
T0–T24 (n = 63) 45.87 (22.31) 47.22 (24.86) NS 48.73 (2
MCP
T0–T4 (n = 142) 76.72 (18.63) 83.57 (10.65) <0.001 85.03 (9
T0–T24 (n = 103) 82.28 (10.65) 84.56 (9.26) 0.007 85.09 (9
Knee
T0–T4 (n = 152) 116.01 (15.07) 121.25 (15.59) <0.001 123.49 (1
T0–T24 (n = 85) 115.94 (13.82) 120.14 (17.36) 0.009 122.17 (1
Ankle
T0–T4 (n = 98) 28.59 (13.91) 32.34 (13.26) <0.001 32.85 (1
T0–T24 (n = 45) 33.11 (16.42) 34.22 (16.05) NS 31.77 (1
SD, standard deviation; NS, no statistical difference; MCP, metacarpophala
Statistical test: ANOVA for repeated measures.ation; MCP, metacarpophalangeal joint.
VASSw was the variable with the best response to IAI with
TH at all assessment times for all joints, and with best sta-
tistical signiﬁcance. We  observed a statistical improvement
from T0 at T4, T12 and T24 weeks for all joints, always with
a p < 0.001. This reinforces the hypothesis of the atrophying
properties of TH, possibly causing a decrease in VASSw, a joint
parameter more  objective than the pain.
In the literature, we found that the IAI response durationicular injection with triamcinolone hexacetonide in patients
nd joint inﬂammation parameters. Rev Bras Reumatol. 2016.
may vary according to the disease in question. It is observed
in meta-analyses and systematic reviews that the typical
response duration to IAI in OA patients is (typically) from
 for each joint studied.
on in degrees – Mean (±SD)
 p T12 p T24 p
2.99) <0.001 – – – –
.45) <0.001 – – – –
.40) NS 126.47 (10.27) NS 128.52 (7.01) NS
9.16) <0.001 – – – –
1.53) NS 48.53 (22.66) NS 46.50 (20.62) NS
.40) <0.001 – – – –
.54) <0.001 85.19 (9.94) <0.001 84.51 (11.42) 0.011
7.26) <0.001 – – – –
4.22) <0.001 121.29 (13.02) <0.001 120.14 (14.26) 0.002
4.51) <0.001 – – – –
6.99) NS 33.22 (17.22) NS 32.00 (16.69) NS
ngeal joint.
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Table 6 – Assessment of improvement in joint extension over time for each joint studied.
Joint Joint extension in degrees – Mean (±SD)
T0 T1 p T4 p T12 p T24 p
Elbow
T0–T4 (n = 48) −4.79 (18.67) −2.39 (13.87) NS −2.04 (15.23) NS
T0–T24 (n = 17) 8.52 (20.67) 5.58 (15.50) NS 6.47 (15.81) NS 6.17 (15.36) NS 5.88 (13.92) NS
Wrist
T0–T4 (n = 160) 41.58 (20.35) 45.34 (19.75) <0.001 47.46 (20.18) <0.001
T0–T24 (n = 62) 58.54 (17.16) 60.72 (17.94) NS 60.64 (20.87) NS 63.95 (16.72) <0.001 60.48 (17.54) NS
MCP
T0–T4 (n = 142) 62.55 (34.23) 65.66 (32.62) <0.001 66.93 (31.60) <0.001
T0–T24 (n = 77) 82.20 (10.74) 84.74 (9.13) 0.016 85.19 (9.43) 0.001 85.32 (9.50) 0.003 84.93 (11.39) 0.014
Knee
T0–T4 (n = 152) −3.73 (8.34) 0.44 (6.19) <0.001 0.46 (5.48) <0.001
T0–T24 (n = 85) −2.68 (8.79) 3.09 (5.65) <0.001 2.82 (4.96) <0.001 3.76 (6.66) <0.001 4.30 (6.87) <0.001
Ankle
T0–T4 (n = 98) 11.29 (4.85) 13.17 (5.15) <0.001 14.38 (5.46) <0.001
T0–T24 (n = 45) 13.56 (5.10) 13.84 (5.87) NS 14.77 (5.70) NS 14.09 (4.97) NS 12.54 (6.41) NS
phala
rSD, standard deviation; NS, no statistical difference; MCP, metacarpo
Statistical test: ANOVA for repeated measures.
only one to two weeks, reported a maximum of 4 weeks.12–14
These results are quite different from ours, which showed sus-
tained response (improvement) to IAI with TH for at least four
weeks for all variables in all assessed joints. On assessing
the VASs, most of the joints showed sustained response
up to 12 weeks. For MCPs and knee joints, we observed
sustained response until T24, not only for the three VASs
variables, but also for the joint goniometry of ﬂexion and
extension.
As regards juvenile idiopathic arthritis (JIA), systematic
reviews have shown a response to the CE IAI with a maxi-
mum duration of 1 year and 3 months to 1 year and 8 months,
depending on the study. In these studies, the predictors of
increased response to IAI were “current use of methotrexate”,
“knee injected”, “use of TH for IAI” and “current use of CE at
the time of IAI”.15–18 In our study, knee also showed an excel-
lent response. But our follow-up time of patients was much
shorter, only 24 weeks.
The joints that showed statistical improvement after IAI
with TH for all variables and times points studied in our study
were the MCPs and knees. This ﬁnding may be due, among
other causes, to the excellent accuracy of the IAI in those
joints, as determined by Lopes et al.19 These authors found an
accuracy of 100% and 97% for IAIs with TH performed blindly
and respectively for knees and MCPs.
We can point some limitations of the present study. We
can mention the intragroup analysis; the non-homogeneous
distribution of the kinds of injected joints (particularly the
low number of shoulders) and follow-up time; the lack of
a functional assessment (ex: HAQ) at the time-points; the
lack of long-term follow-up. The following are also limita-
tions of the present study: the absence of analysis between
pre-injected and ﬁst-injected joints, the absence of analysis of
injection accuracy and the absence of analysis of the correla-
tion between the use of antirheumatic drugs and the presencePlease cite this article in press as: Furtado RN, et al. Intra-ar
with rheumatoid arthritis: prospective assessment of goniometry a
http://dx.doi.org/10.1016/j.rbre.2016.08.001
of articular deformity with the response to IAI; and, moreover,
the absence of a more  objective assessment tool, such as the
articular ultrasound. The absence of any method of statisticalngeal joint.
correction for multiple comparisons can also be considered a
limitation.
Moreover, the applicability of our work is relevant. Through
it, we identiﬁed that joint swelling is the variable that best
responds to IAI with TH in a large cohort of patients evalu-
ated prospectively and “blindly”. This reinforces the indication
of TH use to promote chemical synovectomy in RA patients
with refractory synovitis. Another interesting ﬁnding in our
study is the evidence of a poor response in joint goniometry
in the medium term after IAI with TH. Therefore, we  should
not always expect signiﬁcant changes in joint goniometry after
IAI with CE, even in joints that improved pain and swelling.
This study corroborates the statement of IAI with TH for
treatment of refractory synovitis in RA patients. Joint swelling
was identiﬁed as the variable with the best response to this
procedure, and the knees and MCPs as the joints with the best
response to it. More prospective studies are required to deﬁne
other variables such as the optimal dose of TH and the exact
duration of response after IAI.
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